Ron Cohen
Chief Executive Officer Oryon Cell Therapies
Seminars
Wednesday 9th September 2026
Advancing Autologous iPSC-Derived Dopaminergic Neurons Clinical Development
9:00 am
- Presenting safety and engraftment data from an iPSC-derived neuronal therapy in Parkinson’s disease
- Evaluating early clinical signals and defining meaningful endpoints for regenerative neurology
- Demonstrating manufacturing comparability and critical quality attribute control while scaling toward pivotal development
- Aligning CMC and regulatory strategy to support durability claims and patient follow-up
